(Q37345868)

19 August 2017

1 reference

title

Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

19 August 2017

1 reference

0 references

1 reference

1 reference

1 reference

Nila Rafiq

1

1 reference

19 August 2017

Zobair M Younossi

series ordinal

2

1 reference

19 August 2017

publication date

1 April 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

207-215

1 reference

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Impact of obesity on treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.207

21 January 2018

Identifiers

DOI

10.1586/17474124.2.2.207

1 reference

19 August 2017

1 reference